Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

10.4158/EP.8.6.439

10.1002/1097-0142(19811115)48:10<2267::AID-CNCR2820481023>3.0.CO;2-R

American College of Physicians/American Society of Internal Medicine, 2002, Disease Management Module on Male Hypogonadism

10.1038/bjc.1993.293

Andropause Consensus Panel, 2001, Proceedings of the Andropause Consensus Panel

10.1046/j.1365-2265.1997.3071113.x

10.1016/S0022-5347(05)66519-6

Barrett‐Connor E., 1990, A prospective, population‐based study of androstenedione, estrogens, and prostatic cancer, Cancer Res, 50, 169

10.1111/j.1365-2265.1994.tb03929.x

Beland G., 1990, A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma, Cancer, 66, 1074, 10.1002/cncr.1990.66.s5.1074

10.1016/S0022-5347(17)49698-4

10.1002/j.1939-4640.2001.tb02570.x

10.1210/jc.83.9.3155

10.1056/NEJM199607043350101

10.1152/ajpendo.2001.281.6.E1172

10.1016/S0022-5347(17)35617-3

Carter HB, 1993, PSA velocity for the diagnosis of early prostate cancer. A new concept, Urol Clin North Am, 20, 665, 10.1016/S0094-0143(21)00919-8

10.1016/S0090-4295(99)80049-1

10.1016/S0022-5347(17)40078-4

10.1001/jama.1997.03540420048028

10.1016/S0090-4295(99)80181-2

10.1016/S0022-5347(01)65871-3

10.1002/j.1939-4640.1997.tb01964.x

10.1159/000181314

10.1016/S0090-4295(99)00153-3

Dorgan JF, 1998, Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland, Cancer Epidemiol Biomarkers Prev, 7, 1069

10.1002/jso.2930590410

10.1038/sj.bjc.6690445

10.1016/S0090-4295(02)01646-1

10.1016/S0090-4295(01)01304-8

10.1016/S0022-5347(17)54531-0

10.1093/jnci/88.16.1118

10.1001/jama.1995.03520280035036

10.1097/00007611-199007000-00016

10.1073/pnas.94.7.3320

10.1002/j.1939-4640.1994.tb00433.x

10.1056/NEJM199210223271701

10.3322/canjclin.50.1.7

10.4158/EP.6.2.132

Guess HA, 1997, 5 Alpha‐reductase activity and prostate cancer: a case‐control study using stored sera, Cancer Epidemiol Biomarkers Prev, 6, 21

Guileyardo JM, 1980, Prevalence of latent prostate carcinoma in two U.S. populations., J Natl Cancer Inst, 65, 311

10.1093/oxfordjournals.aje.a008832

Hajjar RR, 1997, Outcomes of long‐term testosterone replacement in older hypogonadal males: a retrospective analysis, J Clin Endocrinol Metab, 82, 3793, 10.1210/jcem.82.11.4387

10.1210/jc.81.12.4400

10.1210/jcem.86.2.7219

Hawk E., 2000, Male pattern baldness and clinical prostate cancer in the epidemiologic follow‐up of the first National Health and Nutrition Examination Survey, Cancer Epidemiol Biomarkers Prev, 9, 523

10.1002/(SICI)1097-0142(19990715)86:2<312::AID-CNCR15>3.0.CO;2-7

10.1016/S0022-5347(05)67812-3

10.1002/pros.2990230203

Hong JH, 2002, Oral testosterone replacement in Korean patients with PADAM, Aging Male, 5, 52, 10.1080/tam.5.1.52.56

Hsing AW, 2001, Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population‐based case‐control study, Cancer Epidemiol Biomarkers Prev, 10, 1077

Hsing AW, 1993, Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer, Cancer Epidemiol Biomarkers Prev, 2, 27

10.1093/oxfordjournals.epirev.a000792

10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B

Huggins C., 1941, Studies on prostate cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res, 1, 293

10.1002/pros.2990110208

10.1001/jama.280.7.605

Jackson MA, 1977, Characterization of prostatic carcinoma among blacks: a continuation report, Cancer Treat Rep, 61, 167

Jackson MA, 1981, Factors involved in the high incidence of prostatic cancer among American blacks, Prog Clin Biol Res, 53, 111

10.3322/canjclin.52.1.23

10.1046/j.1365-2265.2001.01240.x

10.1016/S0022-5347(01)66154-8

10.1210/jc.81.12.4358

10.1016/S0950-351X(97)80302-3

10.1093/gerona/56.5.M266

10.1016/S0094-0143(05)70375-X

10.3322/canjclin.48.1.6

10.3322/canjclin.49.1.8

10.1200/JCO.1988.6.9.1456

10.1159/000030198

10.1155/2000/683607

10.1093/gerona/57.2.M76

10.1056/NEJM199802263380901

10.1016/S0090-4295(96)00445-1

10.1016/0022-4731(89)90352-X

10.1210/jcem-54-6-1104

10.1016/S0304-3835(01)00473-6

10.1016/S0090-4295(00)01116-X

Morales A., 2002, International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late‐onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male, Aging Male, 5, 74, 10.1080/tam.5.2.74.86

10.1056/NEJM199608013350502

10.1001/jama.1996.03540230054035

10.1016/S0026-0495(97)90057-3

10.1111/j.1532-5415.1993.tb02049.x

Neri B., 1989, Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side‐effects, Anticancer Res, 9, 13

Nomura A., 1988, Prediagnostic serum hormones and the risk of prostate cancer, Cancer Res, 48, 3515

Nomura AM, 1996, Serum androgens and prostate cancer, Cancer Epidemiol Biomarkers Prev, 5, 621

10.1001/jama.1993.03510070082041

10.1016/S0022-5347(01)64708-6

10.1507/endocrj.44.719

Polascik TJ, 1999, Prostate specific antigen: a decade of discovery—what we have learned and where we are going, J Urol, 16, 293

10.1016/0090-4295(93)90364-G

10.1016/S0022-5347(05)67962-1

Sakr WA, 1994, High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases, In Vivo, 8, 439

10.1016/0960-0760(90)90475-Z

10.1007/BF02550407

10.1002/pros.1046

Schmitt B., 2000, Cochrane Database Syst Rev, 2

10.1200/JCO.2000.18.4.847

10.1080/014850101753145861

Sih R., 1997, Testosterone replacement in older hypogonadal men: a 12‐month randomized controlled trial [see comments], J Clin Endocrinol Metab, 82, 1661, 10.1210/jcem.82.6.3988

10.1210/jc.86.6.2437

10.2165/00002512-200017060-00001

10.1016/S0022-5347(17)32528-4

10.1046/j.1365-2265.2000.01152.x

10.1210/jc.85.8.2670

10.1210/jc.84.6.1966

10.1210/jc.84.8.2647

10.1016/S0022-5347(01)64126-0

10.1210/jc.75.4.1092

Tenover JS, 1998, The 80th Endocrine Society Meetings

10.1016/S0022-2143(99)90048-3

Urban RJ, 1995, Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis, Am J Physiol, 269, E820

Vatten LJ, 1997, Androgens in serum and the risk of prostate cancer: a nested case‐control study from the Janus serum bank in Norway, Cancer Epidemiol Biomarkers Prev, 6, 967

10.1210/jc.85.8.2839

Wenzl TB, 1998, Variation in PSA values in patients without malignancy, Urology, 52, 932

10.1093/jnci/89.11.820

10.1001/jama.288.3.321

10.1016/S0015-0282(16)58166-7

10.1093/oxfordjournals.aje.a009326

10.1002/pros.2990030607